ClinicalTrials.gg

Clostridium Infections clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 251 studies for Clostridium Infections across more than 10 countries. 51 are recruiting or about to start. 222 of them are mainly about Clostridium Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 3 narrower conditions too, such as Tetanus: 622 studies, 86 open.

Status

Completed
130
Recruiting
36
Terminated
30
Status unknown
22
Not yet recruiting
14
Withdrawn
12

Phase

Phase 2
58
Phase 3
47
Phase 1
35
Phase 4
22
Early Phase 1
4

Where

United States
121
Canada
48
France
17
United Kingdom
17
Spain
16
Germany
15

Who develops what

Add Clostridium Infections to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 3 with this as their studies’ main aim; 0 with a live phase 3 study; 2 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
FidaxomicinRecent, limited
Evidence
  • NCT05201079 · Mikrobiomik Healthcare Company S.L. · Phase 3 · comparator · “Fidaxomicin” · registered Dec 2021
  • NCT02784002 · Summit Therapeutics · Phase 2 · comparator · “Fidaxomicin” · registered May 2016
Astellas Pharma Inc58% of its industry studiesUS: off-patent, 5 generics marketedEU: Zeria Pharmaceutical (EMA 2011)11 study
VancomycinEarlier only
Evidence
  • NCT04802837 · Summit Therapeutics · Phase 3 · comparator · “Vancomycin” · registered Mar 2021
  • NCT04247542 · Acurx Pharmaceuticals Inc. · Phase 2 · comparator · “Vancomycin” · registered Jan 2020
  • NCT03595553 · Summit Therapeutics · Phase 3 · comparator · “Vancomycin” · registered Jun 2018
  • NCT03105479 · Johnson & Johnson · Phase 3 · comparator · “Vancomycin capsule” · registered Mar 2017
  • NCT02218372 · Astellas Pharma Inc · Phase 3 · comparator · “Vancomycin capsules” · registered Aug 2014
Pfizer27% of its industry studiesUS: off-patent, 32 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 20 Apr 2027 est.ombetoxabart · AstraZeneca · Phase 2 main aimNCT07285213 Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody — primary endpoint: First occurrence of recurrence of C difficile infection · 230 enrolled
  • 29 Sept 2027 est.Ibezapolstat · Acurx Pharmaceuticals Inc. · Phase 2 main aimNCT07513285 ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection — primary endpoint: Evaluate the rate of CDI Clinical Cure (CC) · 20 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Clostridium Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Proton pump inhibitors (PPIs) 3

Coming up

15studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 36 Clostridium Infections studies recruiting now, 22 (61%) set no upper age limit and 8 (22%) stop at 75 or younger. 9 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (8%) take healthy volunteers.

Recruiting studies that take each age, of 36
AgeWomenMen
105 (14%)5 (14%)
1833 (92%)33 (92%)
3033 (92%)33 (92%)
4033 (92%)33 (92%)
5032 (89%)32 (89%)
6532 (89%)32 (89%)
7531 (86%)31 (86%)
8528 (78%)28 (78%)

Across all 251 studies, recruiting or not: 14% stop at 75 or younger and 10% at 65; 18% take children; <1% are for women only and <1% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Clostridium Infections studies take

Of 23 phase 2 interventional studies under Clostridium Infections, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 121 mo13–28 · 14 studies——
Phase 223 mo19–39 · 23 studies——
Phase 337 mo34–46 · 23 studies——
Interventional, no phase29 mo9–37 · 27 studies——
Observational31 mo22–… · 26 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 251. Browse all 251 → or search them.